Tamsulosin effect on the treatment of urinary tract obstruction symptoms in women

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230501058042N1

Enrollment

Registered

2023-05-10

Start date

2023-05-04

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary obstruction symptoms.

Interventions

Intervention group: Tamsulosin drug with a dose of 0.4 mg daily.

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Female Over 18 years old With urinary tract obstruction symptoms

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
IPSS Score. Timepoint: At the beginning of the study and 4 weeks after taking the drug. Method of measurement: IPSS questionnaire.	—

Secondary

Measure	Time frame
The result of uroflowmetry. Timepoint: The beginning of the study and 4 weeks after the start of taking the drug. Method of measurement: Objective uroflowmetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Lotfi

Sabzevar University of Medical Sciences

rabiet94@medsab.ac.ir+98 51 4401 8001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026